Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes

Abraham Neelankal John

doi:10.26182/5deda75c162a7

Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes

Abraham Neelankal John

UWA Medical School

Research output: Thesis › Doctoral Thesis

162 Downloads (Pure)

Abstract

To enhance the knowledge of β-cell dedifferentiation (BCD) and its causal role in Type 2 diabetes (T2D), my studies employed β-cell line mouse insulinoma 6 (MIN6) and db/db islets from T2D model mice thereby establishing those as models of dedifferentiation. Vitamin D receptor (VDR)-targeted therapy that employed LCA propionate was utilized to treat early passage MIN6 and db/+ mice islets in the pre-diabetic state to protect β-cell from undergoing dedifferentiation. Furthermore, my research using MIN6 and db/db also identified a novel druggable compound ANJR12947285, which has the potential to induce redifferentiation in dedifferentiated β-cell.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Jiang, Fang-Xu, Supervisor Morahan, Grant, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	20 Jul 2018
DOIs	https://doi.org/10.26182/5deda75c162a7
Publication status	Unpublished - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.26182/5deda75c162a7

THESIS - DOCTOR OF PHILOSOPHY - NEELANKAL JOHN Abraham - 2018
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cite this

@phdthesis{c6657e7cfc674dc39a5104d6af3208bf,

title = "Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes",

abstract = "To enhance the knowledge of β-cell dedifferentiation (BCD) and its causal role in Type 2 diabetes (T2D), my studies employed β-cell line mouse insulinoma 6 (MIN6) and db/db islets from T2D model mice thereby establishing those as models of dedifferentiation. Vitamin D receptor (VDR)-targeted therapy that employed LCA propionate was utilized to treat early passage MIN6 and db/+ mice islets in the pre-diabetic state to protect β-cell from undergoing dedifferentiation. Furthermore, my research using MIN6 and db/db also identified a novel druggable compound ANJR12947285, which has the potential to induce redifferentiation in dedifferentiated β-cell. ",

keywords = "Dedifferentiation of MIN6, Dedifferentiatiom db/db islets, Chemical treament to protect dedifferentiation of beta cells, Chemical treatment to redifferentiate dedifferentiated islets beta-cells",

author = "{Neelankal John}, Abraham",

year = "2018",

doi = "10.26182/5deda75c162a7",

language = "English",

school = "The University of Western Australia",

}

TY - BOOK

T1 - Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes

AU - Neelankal John, Abraham

PY - 2018

Y1 - 2018

N2 - To enhance the knowledge of β-cell dedifferentiation (BCD) and its causal role in Type 2 diabetes (T2D), my studies employed β-cell line mouse insulinoma 6 (MIN6) and db/db islets from T2D model mice thereby establishing those as models of dedifferentiation. Vitamin D receptor (VDR)-targeted therapy that employed LCA propionate was utilized to treat early passage MIN6 and db/+ mice islets in the pre-diabetic state to protect β-cell from undergoing dedifferentiation. Furthermore, my research using MIN6 and db/db also identified a novel druggable compound ANJR12947285, which has the potential to induce redifferentiation in dedifferentiated β-cell.

AB - To enhance the knowledge of β-cell dedifferentiation (BCD) and its causal role in Type 2 diabetes (T2D), my studies employed β-cell line mouse insulinoma 6 (MIN6) and db/db islets from T2D model mice thereby establishing those as models of dedifferentiation. Vitamin D receptor (VDR)-targeted therapy that employed LCA propionate was utilized to treat early passage MIN6 and db/+ mice islets in the pre-diabetic state to protect β-cell from undergoing dedifferentiation. Furthermore, my research using MIN6 and db/db also identified a novel druggable compound ANJR12947285, which has the potential to induce redifferentiation in dedifferentiated β-cell.

KW - Dedifferentiation of MIN6

KW - Dedifferentiatiom db/db islets

KW - Chemical treament to protect dedifferentiation of beta cells

KW - Chemical treatment to redifferentiate dedifferentiated islets beta-cells

U2 - 10.26182/5deda75c162a7

DO - 10.26182/5deda75c162a7

M3 - Doctoral Thesis

ER -

Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this